-
Conference Room 3 - IX Investor 08, 14th March 2008, ExCeL London
-
Introduction by Andy Hartwill, Head of Research, Objective Capital
Objective Capital - Breaking the Silence!
Regular stock market investors know only too well the frustration that arises from buying shares in a company, maybe on the back of a news story or broker's recommendation - and then nothing. Complete silence.
Regular corporate research; objective, incisive and accessible, is the lifeblood of markets. Without it there is often confusion. Should I buy or sell? Is anything happening? Has the story changed? What ought my expectations to be? In this vacuum it is easy to make the wrong decision.
For so many smaller companies this is the case. Companies that often have the best stories to tell have no one to tell them. That is why small companies are increasingly sponsoring investment research.
Objective Capital is an independent research company. We produce research on all sectors and all markets. Taking place at IX Investor 08 on the 14th March from 10am, we are running a series of 15-minute themed company presentations with a panel to answer questions at the end of each session. There will be an opportunity to meet the speakers over coffee, too. You are most welcome, simply register in advance for your free entry ticket by clicking here.
If you would like to receive our research reports on a regular basis you can sign up on our website - it is free - www.objectivecapital.co.uk
Objective Capital Small Cap Investors Forum - Programme events
- Session one: 10 -11.30am Introduction and Misc. Small Caps
- Session two: 12.00 - 1.00 Mines & Minerals
- Session three: 2.00pm - 3.00pm Clean Technology
- Session four: 3.15pm - 4.15pm Biotech & Pharma
Confirmed speakers include
- Objective Capital - Andy Hartwill, Head of Research
- FirstArtist - Richard Hughes, Group MD
- London Capital - Simon Denham, Chief Operating Officer
- Conroy Diamonds and Gold plc - Maureen Jones, Managing Direcor
- Scandinavian Minerals Ltd - Peter Walker, President & CEO
- Phynova - Robert Miller, CEO
- BioProspect - Peter Landau, Non-Executive Director
- LiDCo - Terry O'Brien, CEO
- Bluewater Bio - Daniel Ishag, CEO
BioProspect http://www.bioprospect.com/
Australian owned and managed, BioProspect is one of Australia's emerging natural compound and product development companies that is conducting research and early-stage commercialisation in the pesticide and agricultural sectors.
Peter Landau - Non-Executive Director
Mr. Landau is a corporate lawyer and corporate advisor having previously worked with Grange Consulting Group, Clayton Utz and as general counsel at Co-operative Bulk Handling. Mr. Landau is responsible for providing general corporate, capital raising, transaction and strategic advice to numerous ASX listed and unlisted companies. Mr. Landau is a Director of a number of ASX listed companies with particular focus on mining, oil and gas exploration and development in Australia and Africa.
FirstArtist Corporation plc http://www.firstartist.com/
First Artist Corporation plc is one of the leading integrated media, events and entertainment/sport management businesses. Our companies are recognised experts in entertainment and sport representations, new media and advertising, sponsorship and live events.
Richard Hughes, Group Managing Director
Richard joined First Artist in the spring of 2004. He began his career in the corporate event management and hospitality sector and subsequently spent 16 years in marketing communications, gaining extensive commercial and financial management experience with both major multinational groups and niche brand strategic development businesses. He has previously filled the role of finance director for both fully listed and private groups with a strong focus on acquisition.
London Capital Group http://www.londoncapitalgroup.co.uk
London Capital Group Ltd is a rapidly growing financial services company offering online trading. Its core activities are the provision of spread betting products on the financial markets to retail clients under the trading name Capital Spreads, online foreign exchange trading services to institutional and intermediate clients under the Capital Forex brand and institutional derivatives broking under the name Capital Derivatives.
Simon Denham, Chief Operating Officer
Simon designed, commissioned and runs the spread betting division of LCG. He joined LCG in March 2003 and the joined the board of LCG in October 2003. Prior to this, Simon ran the options and derivatives desk at Cantor Index specialising in spread betting for the general public. Before Cantor Index, Simon worked for Christiania Bank, where he launched the bank's interest rate derivatives and options desk, trading in swaptions, swaps, caps/floors, futures, FRAs and government and corporate bonds. Before Christiania Bank, Simon worked for Bank of Nova Scotia, where he was responsible for the inter-bank and corporate swap market-making in Italian Lira and Spanish Peseta.
Conroy Diamonds and Gold plc http://www.conroydiamondsandgold.com/
The primary objective of your Company, is an Irish-registered and incorporated company, is to establish a new gold province in Ireland through the discovery and bringing into production of one or more gold deposits. Exploration to date in the Longford-Down Massif has established a gold trend extending for at least fifty miles along strike from Co. Armagh, through Co. Monaghan and into Co. Cavan.
Maureen Jones, Managing Director
Ms. Jones joined Professor Conroy in the formation of Conroy Diamonds and Gold, and has been managing director since 1998. They began working together at Conroy Petroleum and Natural Resources in 1980, where she served as a director of the company from 1986 until 1994. Maureen also has a medical background, as a radiographer specialising in nuclear medicine. She became a manager with International Medical Corp. in 1977.
Scandinavian Minerals Ltd http://www.scandinavianminerals.com/
Scandinavian Minerals Limited is a Canadian public company listed on the Toronto Stock Exchange under the symbol SGL. The Company's corporate objective is the exploration and development of base and precious metal properties in northern Europe. Current focus is the development of its 100% owned Kevitsa nickel - copper - PGE property in northern Finland.
Peter Walker, President & CEO
B.Sc., A.R.S.M., Royal School of Mines, Imperial College, London. Geologist. Over 30 years international experience in metals marketing, trading and investment. Founded company in 1996.
Phynova Group plc http://www.phynova.com/
Phynova was founded in July of 2002 to develop drugs that satisfy unmet therapeutic needs in areas such as: infectious disease, metabolic disease and cancer. The Company's headquarters are located in Blenheim Office Park in Oxford. Phynova is developing Drug Candidates which are mainly derived from botanical medicines and have proved effective and safe in clinical use in China. The Chinese have been using botanical medicines for thousands of years and over that time have built up a wealth of knowledge and expertise in the medicinal use of plants.
Robert Miller, Chief Executive Officer
Robert has had over 20 years' experience in the natural products industry in both the United States and Europe. He is one of the main individuals responsible for the establishment of Chinese herbal medicine in the UK. He has had broad experience in the areas of product development, manufacturing, quality control and regulatory affairs relating to natural products. In 1997 he founded East West Biotech Limited, a company using proteomic technology for the development and quality control of botanical drugs whose assets were acquired by Oxford Natural Products Limited ("ONP") in 1999. Following the acquisition he was responsible for business development at ONP until October 2000.
LiDCO Group plc http://lidco-ir.co.uk/html/company
LiDCO Group was founded in 1991 by Dr Terry O'Brien, Dr David Band, Dr Robert Linton and Dr Jiri Kratochvil in collaboration with the United Dental and Medical Schools of St Thomas' and Guys Hospitals (now King's College, London.) The Group has developed inventions within the cardiovascular monitoring field resulting from research in the Applied Physiology Laboratory based on the St Thomas' Hospital campus. LiDCO has a licence to exploit a range of inventions arising from research within the department. LiDCO Limited, the Group's principal trading subsidiary was funded predominantly by private equity funding raised from a number of institutional and private investors such as the Merlin Biosciences Fund LP. On July 5th 2001 LiDCO Group became a PLC when it successfully floated on AiM.
Terry O'Brien, CEO
Dr O'Brien co-founded the Group in 1991. Prior to that, he has held senior positions with biomedical companies including Sandoz SA, Pharmacia AB, Meadox Medical Inc, Novamedix Ltd, Enzymatix Ltd and Surgicraft Ltd. Dr O'Brien was associate commercial director at Enzymatix, which subsequently listed on the London Stock Exchange as ChiroScience Plc. Over the last 25 years Dr O'Brien has been involved in the research and development and subsequent marketing of a number of medical device technologies that are now standards of care in the anesthesia, critical care and surgery markets.
Bluewater Bio International http://www.bluewaterbio.com
Bluewater Bio provides market leading environmental technologies, combined with innovative design and build solutions for water and wastewater treatment. The Company is a technology and process engineering business offering a global service of leading edge solutions, reliable quality, and broad experience in water and wastewater treatment for Industrial, Municipal, and Commercial clients.
Daniel Ishag, Chief Executive Officer
In 2000 Daniel Ishag founded e-Spotting Media, an internet company which merged in February 2004 with NASDAQ listed FindWhat.com valuing e-Spotting at US$170m. This was a new business concept in online advertising, which is now the fastest growing area of online advertising and currently accounts for 57.1% of total online media spend. During this four year period e-Spotting grew to a 240 employee pan-European company that operated 10 offices, in 8 languages, 5 currencies, and serviced over 23,000 clients. Prior to e-Spotting Daniel was an investment banker at Hirsch & Cie. He has also gained international business experience in many emerging markets, with focus across Asia and Africa.
